Solventum saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 77 to 82.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks matches up against that of all other stocks.
History reveals that the best stocks typically have an RS Rating of at least 80 in the early stages of their moves.
Solventum is working on a consolidation with an 85.92 entry. See if it can clear the breakout price in heavy trade.
While earnings-per-share growth declined in the company's most recently reported quarter from -35% to -36%, sales rose 3%, up from 2% in the previous report.
Solventum holds the No. 30 rank among its peers in the Medical-Products industry group. Boston Scientific, Insulet and Penumbra are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
